Reaction profile
The FDA adverse-event record for transient blindness
60 FDA reports name transient blindness, a lower-volume reaction in the CVM extract (VeDDRA 1850). Plate stamps and neighbourhood peers follow.
- #1656 of 2,481
- by report volume (all reactions)
- 60
- reports citing this reaction
- 6.7%
- death-coded share
- Dog
- most-affected species
Release-over-release change
What changed in the latest FDA data snapshot
PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Transient blindness has 60 reports now versus 60 in that prior snapshot: 0 the same number of (0.0%).
- Report change
- +0
- Death-coded reports
- +0
- Death-coded share
- −0.0 pts
This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.
Subscribe to Transient blindness changesFDA AER · VeDDRA plate
Code 1850 VOL-LOW
VOL-LOW · DEATH-PAR · MID-PACK · PHOTO-FINISH · SPECIES-DOG · DRUG-LEAD · DESK-WIDE · BOOK-FULL
- VOL-LOW 60 reports
- DEATH-PAR 6.7%
- MID-PACK #1656/2481
- PHOTO-FINISH Foam in the trachea
- SPECIES-DOG Dog · 39
- DRUG-LEAD Milbemycin Oxime… · 10
- DESK-WIDE 20 breeds
- BOOK-FULL 8/8 fields
Nearest volume peer: Foam in the trachea (±0 reports)
Instrument codes from this reaction’s FDA CVM adverse-event extract: volume band, death-coded share, corpus rank, photo-finish peer, lead species, lead drug, breed desk, and book completeness. Not a clinical diagnosis.
Lower-volume neighbourhood around Transient blindness
Lower-third volume poles plus nearest peers, not a full reaction corpus board reprint.
Transient blindness: low death-coded share in the FDA AER plate
Signature read: 4 death-coded reports is a thin tail count for Transient blindness in the CVM extract. Report volume is lower-third scale: 60 named reports in the openFDA extract. Death-coded share is lower-third: 4 of 60 reports (6.7% of named reports). Nearest volume peer: Foam in the trachea (±0 reports). Lead species Dog (39). Lead co-reported drug Milbemycin Oxime + Spinosad (10).
Read these counts as reporting volume, not risk: per our methodology, Lead co-reported drug Milbemycin Oxime + Spinosad appears in filings alongside this reaction; that is association, not causation. Browse the full reactions index or the about page for how PlainBreed frames FDA CVM extracts.
Species Most Affected
Breeds Most Affected
Associated Drugs
Nationwide reactions with similar profiles
Two openFDA-derived peer sets for Transient blindness, both floored at ≥50 reports so the neighborhoods stay in the advertised mass (the volume chart above is the unfloored photo-finish strip).
Similar report volume
Nearest other reactions by FDA report count (60 here).
Similar death-coded share
Nearest other reactions by death-coded share (6.7% here), distinct from the volume row.
What to do with this reaction
- Compare Transient blindness's report profile against similar reactions nationwide. See similar reactions
- Read how death-coded share differs from a mortality rate before drawing conclusions. Understanding adverse events
- Browse the full reaction directory to compare report counts across reaction types. All reactions
A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.
Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025
Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →